Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109

9518447302
|
Calling
Whatsapp
Get in touch
Download Visual

High-resolution images and Product visuals

Watch Video

Product overview and usage information

Read Literature

Detailed information and research documents

About the Product

Description

Fluxowise O Tablet containing Fluoxetine and Olanzapine is used in neuropsychiatric care for the management of specific mental health conditions. It helps support emotional well-being, balanced mood regulation, and overall psychiatric care under medical supervision.

Fluoxetine works by influencing serotonin levels in the brain, while Olanzapine helps regulate the activity of certain neurotransmitters associated with mood, behavior, and thought processes. Together, they provide complementary neuropsychiatric support.

The tablet is widely prescribed in psychiatric practice as part of comprehensive mental health treatment protocols, leading to consistent prescription demand in specialized healthcare settings.

With increasing awareness of mental healthcare and growing access to psychiatric treatment services, this product offers strong business potential for retailers and distributors. Its established therapeutic relevance, combination approach, and steady market demand make it a reliable product for growth in the neuropsychiatric care segment.

Some patients may experience drowsiness, dizziness, dry mouth, increased appetite, weight gain, fatigue, nausea, constipation, or sleep disturbances. Rarely, severe allergic reactions, movement disorders, metabolic abnormalities, suicidal thoughts, neuroleptic malignant syndrome, or significant changes in blood sugar levels may occur and require immediate medical attention.

Fluxowise O Tablet is indicated for treatment-resistant depression, depressive episodes associated with bipolar disorder, and other psychiatric conditions as determined by a qualified healthcare professional. It helps improve mood, reduce depressive symptoms, and support emotional stability.

This medicine should be used strictly under the supervision of a qualified psychiatrist or healthcare professional. Regular monitoring may be required during treatment. Do not stop taking the medicine abruptly without medical advice. Patients and caregivers should be alert for unusual mood changes, worsening depression, or suicidal thoughts, particularly during the initial stages of treatment.

Store in a cool, dry place below 25°C, protected from moisture and direct sunlight. Keep the tablets in their original packaging and out of reach of children.

Get in Touch

Similar Products

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Fluoxetine 20mg + Olanzapine 5mg Tablet in the PCD pharma franchise market?

This combination tablet is used in psychiatric conditions such as depression with anxiety, treatment-resistant depression, and certain mood disorders, making it a strong CNS and psychiatric segment product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma pharma franchise market.

Why should medical distributors include this combination tablet in their product range?

Medical distributors and wholesalers can benefit from consistent demand in psychiatry clinics, mental health hospitals, and long-term psychiatric treatment prescriptions. It is commonly prescribed by psychiatrists for patients requiring both antidepressant and antipsychotic support in controlled therapy.

Does Cafoli Lifecare offer PCD pharma franchise opportunities for this product?

Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for Fluoxetine + Olanzapine Tablet with monopoly rights, quality psychiatric formulations, competitive pricing, and reliable supply support for distributors and medical agencies.

What benefits do wholesalers get by partnering for this CNS psychiatric product?

Wholesalers and medical agencies benefit from long-term prescription cycles, stable psychiatry demand, and repeat patient therapy usage in mental health management when partnering with Cafoli Lifecare.

How can I become a distributor or franchise partner for this psychiatric combination tablet?

Medical distributors, stockists, wholesalers, and pharma professionals interested in this CNS combination formulation can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, pricing, and distribution support services.

Our Manufacturing Partners

Our Manufacturing Partner | Akums Drugs and Pharmaceuticals
Our Manufacturing Partner | Pharmaceuticals Pvt. Ltd.
Our Manufacturing Partner | Tirupati
Our Manufacturing Partner | Swess-Garniers
Our Manufacturing Partner | Windlas Biotech Limited
Our Manufacturing Partner | Hetero Pharmaceutical company
Our Manufacturing Partner | Unimarck
Our Manufacturing Partner | mascort
Our Manufacturing Partner | Synokem Pharmaceuticals Limited
Our Manufacturing Partner | Biodeal Pharmaceuticals Limited